Dark Blue Therapeutics

News

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

News

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.